/CATB

CATB Stock - Catabasis Pharmaceuticals, Inc.

Q: What is the analyst price target for CATB?

Analyst price target information is not currently available for CATB.

Q: What is CATB's market cap?

Market capitalization information is not currently available for CATB.

Healthcare|Biotechnology|NASDAQ

$8.54-6.97%

$0.64 (-6.97%) • Sep 9

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $9.39

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CATB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.66

52W High$10.26

52W Low$1.25

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024
Revenue	N/A
Gross Profit	N/A
Gross Margin	N/A
Operating Income	$-111,558,000
Net Income	$-94,260,000
Net Margin	N/A
EPS	$-1.68

Company Overview

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

Visit Website

Frequently Asked Questions about CATB

What is CATB's current stock price?

Catabasis Pharmaceuticals, Inc. (CATB) is currently trading at $8.54 per share. The stock has moved -6.97% today.

What is the analyst price target for CATB?

No analyst price targets are currently available for this stock.

What sector is Catabasis Pharmaceuticals, Inc. in?

Catabasis Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CATB's market cap?

Catabasis Pharmaceuticals, Inc. has a market capitalization of $0.23 billion, making it a small-cap company.

Does CATB pay dividends?

No, Catabasis Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.